Drug intelligence / Profile preview

SR-1402

Development stage: Preclinical
Lead developer: Sigmapharm Laboratories
Modality: Small Molecules
Administration: Oral

Overview

SR-1402 is a generic small-molecule pharmaceutical formulation developed by SigmaPharm Laboratories. It is designed as a sustained-release (SR) version of an existing reference listed drug. SigmaPharm specializes in the development of complex generic products using proprietary drug delivery technologies, such as modified-release and sublingual systems. SR-1402 is currently in the regulatory submission phase, with an Abbreviated New Drug Application (ANDA) or New Drug Application (NDA) filed with the U.S. Food and Drug Administration (FDA). As a pipeline product code for a generic manufacturer, the specific active pharmaceutical ingredient (API) and its primary therapeutic indication have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on SR-1402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SR-1402.

Explore the full profile